Sales -3%, adj. EBIT -2m vs. ABGSCe Temporary incoming delivery delays push cash flow into Q1 Optimi...
Redeye comments on further news from the all-important US market.
Redeye finetunes its forecasts for 2025 and beyond following Fortnox’s price increases.
Redeye comments on Enea’s Q4 2024 report, where sales met Redeye Research estimates (RRe) in Enea’s ...
Redeye comments on Evolution’s Q4-results which were in line with our forecasts.
Redeye offers a preview of Doro's Q4 results set to be released on February 13.
We lower adjusted EBITA by 5% for 2025E-27E following the Q4 report.
Nosa Plugs AB (”Nosa Plugs” eller ”Bolaget”) meddelade den 29 januari år 2025 att Bolaget har knutit...
Redeye is encouraged by the recent news regarding Integrum’s increased educational activities, toget...
38% y-o-y sales growth for Catalyst in Q4'24e We leave our EBIT forecasts unchanged ahead of the rep...
On January 29th, Eevia Health Plc (publ) (“Eevia”) announced ten new sales orders for products total...
A good Q4 coming up with 9% revenue and 15% EPS growth 2025 guidance likely to show accelerating gro...
Cost-effective coatings for hydrogen and metallisation applications Seizing opportunities in Chinese...
We forecast Q4 revenue of NOK 243m, +15% y-o-y Doro acquisition closed, could lift '28e EBITA by ~12...
Q4 not likely to be a game-changer New design win with Dell opens large new segment Ambition of 50-6...
This afternoon just before market close, Føroya Banki announced its 2025 net profit guidance range o...
Redeye comments on the outcome of Ngenic’s rights issue, which was subscribed to 88%, injecting Ngen...
According to preliminary information, annual EBITDA will be EUR 4-6m in 2024 (old guidance EUR 4-8m,...
Redeye provides a brief comment on the final rights issue terms announced yesterday.
